Trial · NCT00123474
Outcomes22
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up | 6 months | All randomized imatinib-resistant participants with available data were summarized. | percentage of Participants | NUMBER |
| SECONDARY | Percent of Participants With MCyR At or Prior to 24 Months Follow-Up | 24 months | All randomized imatinib-resistant participants with available data were summarized. | percentage of Participants | NUMBER |
| SECONDARY | Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up | 6 months, 24 months | All randomized imatinib-resistant participants with available data were summarized. | percentage of participants | NUMBER |
| SECONDARY | Time to MCyR in Participants With MCyR at 6 Months Follow-Up | 6 months | Randomized imatinib-resistant participants with MCyR and available data were summarized. | Months | MEDIAN |
| SECONDARY | Time to CHR in Participants With CHR at 6 Months Follow-Up | 6 months | Randomized imatinib-resistant participants with CHR and available data were summarized. | Months | MEDIAN |
| SECONDARY | Time to MCyR in Participants With MCyR at 24 Months Follow-Up | 24 months | Randomized imatinib-resistant participants with MCyR were summarized. | Months | MEDIAN |
| SECONDARY | Time to CHR in Participants With CHR At 24 Months Follow-Up | 24 months | Randomized imatinib-resistant participants with CHR were summarized. | Months | MEDIAN |
| SECONDARY | Number of Participants With MCyR Whose Disease Progressed by 24 Months | 24 months | All imatinib-resistant participants who had achieved MCyR and experienced disease progression were summarized. | participants | NUMBER |
| SECONDARY | Number of Participants With CHR Whose Disease Progressed by 24 Months | 24 months | All imatinib-resistant participants who achieved CHR and then experienced disease progression were summarized. | participants | NUMBER |
| SECONDARY | Number of Participants With MCyR and Baseline BCR-ABL Gene Mutation - All Treated Participants | Baseline up to 24 months | All randomized, treated participants with available mutation data were summarized. | participants | NUMBER |
| SECONDARY | Percent of Imatinib-Resistant Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up | 24, 36, 48, 60, 72, and 84 months | All randomized imatinib-resistant participants were summarized. | percentage of participants | NUMBER |
| SECONDARY | Percent of Imatinib-Resistant Participants With Overall Survival (OS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up | 24, 36, 48, 60, 72, and 84 months | All randomized imatinib-resistant participants were summarized. | percentage of participants | NUMBER |
| SECONDARY | Percent of Participants Intolerant to Imatinib With MCyR at 6 Months and at 24 Months Follow-Up, by QD and BID Schedules and by Total Daily Dose | 6 months, 24 months | All randomized imatinib-intolerant participants with available data were summarized. | percentage of participants | NUMBER |
| SECONDARY | Percent of Participants Intolerant to Imatinib With CHR at 6 Months and at 24 Months Follow-Up | 6 months, 24 months | All randomized imatinib-intolerant participants were summarized. | percentage of participants | NUMBER |
| SECONDARY | Percent of Imatinib Intolerant Participants With Progression Free Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-Up | 24, 36, 48, 60, 72, and 84 months | All randomized imatinib-intolerant participants with available data were summarized | percentage of participants | NUMBER |
| SECONDARY | Percent of Imatinib Intolerant Participants With Overall Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-up | 24, 36, 48, 60, 72, and 84 months | All randomized imatinib-intolerant participants were summarized. | percentage of participants | NUMBER |
| SECONDARY | Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 6 Months Follow-Up | 6 months | All randomized participants were summarized. | percentage of participants | NUMBER |
| SECONDARY | Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 24 Months Follow-Up | 24 months | All randomized participants were summarized. | percentage of participants | NUMBER |
| SECONDARY | Percent of Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up by Dose Schedule and Total Daily Dose - All Randomized Participants | 24, 36, 48, 60, 72, and 84 months | All participants who were randomized to a treatment arm were summarized. | percentage of participants | NUMBER |
| SECONDARY | Percent of Participants Overall Survival at 24, 36, 48, 60, 72, and 84 Months Follow-Up - All Randomized Participants | 24, 36, 48, 60, 72, and 84 months | All participants who were randomized to a treatment arm were summarized. | percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00123474/outcomes